Prevention of onychomycosis reinfection for patients with complete cure of all 10 toenails: Results of a double-blind, placebo-controlled, pilot study of prophylactic miconazole powder 2%

Warshaw, Erin M.; Clair, Katherine R. St.

doi:10.1016/j.jaad.2005.06.019

Cited by 22 publications

(5 citation statements)

References 18 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of the 302 PubMed initial search results, 182 clinical trials (28,352 participants) met inclusion criteria and were included in the final analysis 6–186 . The PRISMA study selection process is detailed in Figure 1.…”

Section: Resultsmentioning

confidence: 99%

Race reporting and representation in onychomycosis clinical trials: A systematic review

Chang

Qiu

Lipner

2021

Mycoses

View full text Add to dashboard Cite

Onychomycosis is the most common nail disorder seen in clinical practice with a prevalence of 8.7%-13.8% in the United States (US). [1][2][3] There has been a trend towards increased racial and ethnic diversity in the United States, with current projections estimating that minority representation will exceed 50% of the population by 2044. 4 Demographic reporting and inclusion of diverse populations within clinical trials is critical to interpret treatment efficacy and prognosis for different groups. A systematic review on racial/ ethnic reporting of dermatology clinical trial participants has been performed, 5 but similar data from onychomycosis clinic trials have not been studied. Our objectives were to systematically review racial/ethnic reporting and representation, as well as, outcomes by race/ethnicity in onychomycosis clinical trials. | MATERIAL S AND ME THODSPubMed was searched in August 2020 for all peer-reviewed, Englishlanguage onychomycosis clinical trials. The keyword 'onychomycosis' was searched with no date ranges, article type filtered for 'Clinical

show abstract

Section: Resultsmentioning

confidence: 99%

Race reporting and representation in onychomycosis clinical trials: A systematic review

Chang

Qiu

Lipner

2021

Mycoses

View full text Add to dashboard Cite

show abstract

“…An increase in minimum inhibitory concentration has been noted in organisms isolated post treatment compared to pretreatment of onychomycosis. [8] We were unable to find any reports of clinical resistance to topical miconazole, but this is a theoretical concern with prophylactic use of this drug.…”

Section: Discussionmentioning

confidence: 99%

Preventing long term relapsing tinea unguium with topical anti-fungal cream: a case report

Arroll

Oakley

2009

Cases Journal

View full text Add to dashboard Cite

BackgroundThe patient was aged 34 when he consulted a dermatologist in Vancouver BC with onychomycosis affecting the right great toenail.Case presentationTrichophyton rubrum was cultured from nail clippings. Griseofulvin was taken for 6 months, resulting in clinical and mycological cure. Over the next 27 years there were multiple relapses. Each course of treatment with oral terbinafine (for up to 18 months) or itraconazole resulted in clinical and mycological cure. A dermatological colleague suggested the reason for relapse was likely to be self re-infection.ConclusionNo clinical relapse has occurred with once-weekly miconazole cream applied to the toenail and webspaces of the right foot over the last four years.

show abstract

“…Little research on prevention of recurrence has been published. In a small pilot study, miconazole 2% powder used twice weekly in shoes and on the feet was not found to be statistically significantly different from placebo powder for prophylaxis of onychomycosis in 48 patients with complete cure of all 10 toenails (93).…”

Section: Recurrence Rates and Prevention Of Reinfectionmentioning

confidence: 97%

Toenail onychomycosis: current and future treatment options

2007

Self Cite

View full text Add to dashboard Cite

Onychomycosis is a common disease affecting as much as 8% of the general population. Treatment of onychomycosis is challenging, complicated by low cure rates and relatively high relapse rates. This paper reviews the efficacy of current oral, topical, and surgical treatment options. Currently, the treatment of choice for toenail onychomycosis is oral terbinafine because of its high efficacy, low relapse rates, and cost-effectiveness. Oral itraconazole or fluconazole could be considered for infections caused by Candida. Topical therapies may be a useful adjunct to these systemic therapies, but are less effective when used alone. More research is needed to determine the best measures for preventing reinfection.

show abstract

Prevention of onychomycosis reinfection for patients with complete cure of all 10 toenails: Results of a double-blind, placebo-controlled, pilot study of prophylactic miconazole powder 2%

Cited by 22 publications

References 18 publications

Race reporting and representation in onychomycosis clinical trials: A systematic review

Race reporting and representation in onychomycosis clinical trials: A systematic review

Preventing long term relapsing tinea unguium with topical anti-fungal cream: a case report

Toenail onychomycosis: current and future treatment options

Contact Info

Product

Resources

About